Table 5.
Proportion of patients maintaining FVIII levels above the threshold (simulation of 1000 patients)
| Dose, IU/kg | Threshold, IU/dL | 2×/week regimena | 3×/week regimenb | ||||
|---|---|---|---|---|---|---|---|
| BAY 81-8973 patients, % | rAHF-PFM patients, % | Ratioc | BAY 81-8973 patients, % | rAHF-PFM patients, % | Ratioc | ||
| 25 | 1 | 27.0 | 6.9 | 3.91 | 69.1 | 34.5 | 2.00 |
| 25 | 3 | 4.0 | 0.5 | 8.00 | 28.1 | 6.8 | 4.13 |
| 25 | 5 | 1.1 | 0 | – | 11.0 | 2.2 | 5.00 |
| 30 | 1 | 33.6 | 10.0 | 3.36 | 75.1 | 40.1 | 1.87 |
| 30 | 3 | 6.2 | 1.1 | 5.64 | 34.7 | 10.0 | 3.47 |
| 30 | 5 | 2.4 | 0.1 | 24.0 | 15.2 | 3.3 | 4.61 |
| 40 | 1 | 42.2 | 14.0 | 3.01 | 81.9 | 50.9 | 1.61 |
| 40 | 3 | 10.4 | 2.4 | 4.33 | 46.6 | 15.1 | 3.09 |
| 40 | 5 | 3.8 | 0.5 | 7.60 | 26.4 | 5.8 | 4.55 |
| 50 | 1 | 49.2 | 18.4 | 2.67 | 85.6 | 58.2 | 1.47 |
| 50 | 3 | 15.3 | 3.5 | 4.37 | 55.2 | 20.4 | 2.71 |
| 50 | 5 | 6.2 | 1.1 | 5.64 | 34.7 | 10.0 | 3.47 |
FVIII factor VIII, rAHF-PFM antihemophilic factor (recombinant) plasma/albumin-free method
aDoses on Monday and Thursday
bDoses on Monday, Wednesday, and Friday
cRatio of BAY 81-8973:rAHF-PFM